KSQ Ther­a­peu­tics sells ear­ly-stage tar­get­ed ther­a­pies to Japan's Ono

As it moves deep­er in­to a Phase I tri­al of its lead pro­gram, KSQ Ther­a­peu­tics is sell­ing a slate of ear­li­er-stage on­col­o­gy pro­grams in ex­change for some cash.

Japan’s Ono Phar­ma­ceu­ti­cal is pay­ing a “dou­ble-dig­it mil­lion up­front” to se­cure mul­ti­ple re­search-stage drugs de­signed to at­tack can­cer by tar­get­ing DNA dam­age re­sponse path­ways. KSQ iden­ti­fied those pro­grams — all with first-in-class po­ten­tial, ac­cord­ing to the com­pa­nies — us­ing its CRISPR screen­ing plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER